1. Market Research
  2. > Biotechnology Market Trends
  3. > Tuberculosis Partnering 2010-2015

Tuberculosis Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
The Tuberculosis Partnering 2010-2015 report provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Tuberculosis Partnering 2010-2015 report provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in tuberculosis partnering deals
Top tuberculosis deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Tuberculosis Partnering 2010-2015 provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of tuberculosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors tuberculosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 100 links to online copies of actual tuberculosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of tuberculosis partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of tuberculosis technologies and products.

Report scope

Tuberculosis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to tuberculosis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in tuberculosis dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 100 tuberculosis deals
The leading tuberculosis deals by value since 2010

In Tuberculosis Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Tuberculosis Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of tuberculosis deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 100 actual tuberculosis deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

tuberculosis, infective, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Tuberculosis Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in tuberculosis partnering

2.1. Introduction
2.2. Tuberculosis partnering over the years
2.3. Big pharma tuberculosis dealmaking activity
2.4. Big biotech tuberculosis dealmaking activity
2.5. Most active tuberculosis dealmakers
2.6. Tuberculosis partnering by deal type
2.7. Tuberculosis partnering industry sector
2.8. Tuberculosis partnering by stage of development
2.9. Tuberculosis partnering by technology type
2.10. Disclosed financial deal terms for tuberculosis
2.10.1 Tuberculosis headline values
2.10.2 Tuberculosis upfront payments
2.10.3 Tuberculosis milestone payments
2.10.4 Tuberculosis royalty rates

Chapter 3 - Leading tuberculosis deals

3.1. Introduction
3.2. Top tuberculosis deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Tuberculosis partnering since 2009
Figure 2: Big pharma - top 50 - tuberculosis deals 2009 to 2014
Figure 3: Big pharma tuberculosis deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - tuberculosis deals 2009 to 2014
Figure 5: Big biotech tuberculosis deal frequency - 2009 to 2014
Figure 6: Tuberculosis dealmaking activity- 2009 to 2014
Figure 7: Tuberculosis partnering by deal type since 2009
Figure 8: Tuberculosis partnering by industry sector since 2009
Figure 9: Tuberculosis partnering by stage of development since 2009
Figure 10: Tuberculosis partnering by technology type since 2009
Figure 11: Tuberculosis deals with a headline value
Figure 12: Tuberculosis deals with upfront payment values
Figure 13: Tuberculosis deals with milestone payments
Figure 14: Tuberculosis deals with royalty rates, %
Figure 15: Top tuberculosis deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...

Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

Use this report to: - Analyze the role biobanks play in the development of new drugs for specific disease treatments. - Learn about the prevailing market size for certain biobank services available ...

Global Markets for Nanocomposites, Nanoparticles, Nanoclays, and Nanotubes

Global Markets for Nanocomposites, Nanoparticles, Nanoclays, and Nanotubes

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Analyze nanocomposites that are in commercial use or under development, associated technologies and applications. - Provide suppliers of advanced materials, entrepreneurs, investors ...

Synthetic Biology: Global Markets

January 2017 $ 6650

Download Unlimited Documents from Trusted Public Sources

Psychotic Disorder Statistics in the UK

  • February 2017
    5 pages
  • Psychotic Disor...  

  • United Kingdom  

View report >

Biological Therapy Industry in the US

  • February 2017
    11 pages
  • Biological Ther...  

    Biotechnology  

  • United States  

    United Kingdom  

View report >

Biological Therapy Industry in the US

  • February 2017
    10 pages
  • Biological Ther...  

  • United States  

View report >

Dna Industry

25 hours ago

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.